JP2023526073A5 - - Google Patents
Info
- Publication number
- JP2023526073A5 JP2023526073A5 JP2022570108A JP2022570108A JP2023526073A5 JP 2023526073 A5 JP2023526073 A5 JP 2023526073A5 JP 2022570108 A JP2022570108 A JP 2022570108A JP 2022570108 A JP2022570108 A JP 2022570108A JP 2023526073 A5 JP2023526073 A5 JP 2023526073A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine composition
- composition according
- smva
- genome
- full
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025238238A JP2026041921A (ja) | 2020-05-17 | 2025-12-08 | 合成改変ワクシニアアンカラ（ｓＭＶＡ）ベースのコロナウイルスワクチン |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063026127P | 2020-05-17 | 2020-05-17 | |
| US63/026,127 | 2020-05-17 | ||
| US202063044033P | 2020-06-25 | 2020-06-25 | |
| US63/044,033 | 2020-06-25 | ||
| US202063113810P | 2020-11-13 | 2020-11-13 | |
| US63/113,810 | 2020-11-13 | ||
| US202163161371P | 2021-03-15 | 2021-03-15 | |
| US63/161,371 | 2021-03-15 | ||
| PCT/US2021/032821 WO2021236550A1 (en) | 2020-05-17 | 2021-05-17 | Synthetic modified vaccinia ankara (smva) based coronavirus vaccines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025238238A Division JP2026041921A (ja) | 2020-05-17 | 2025-12-08 | 合成改変ワクシニアアンカラ（ｓＭＶＡ）ベースのコロナウイルスワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023526073A JP2023526073A (ja) | 2023-06-20 |
| JP2023526073A5 true JP2023526073A5 (https=) | 2024-05-24 |
| JP7788403B2 JP7788403B2 (ja) | 2025-12-18 |
Family
ID=78708032
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022570108A Active JP7788403B2 (ja) | 2020-05-17 | 2021-05-17 | 合成改変ワクシニアアンカラ（ｓＭＶＡ）ベースのコロナウイルスワクチン |
| JP2025238238A Pending JP2026041921A (ja) | 2020-05-17 | 2025-12-08 | 合成改変ワクシニアアンカラ（ｓＭＶＡ）ベースのコロナウイルスワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025238238A Pending JP2026041921A (ja) | 2020-05-17 | 2025-12-08 | 合成改変ワクシニアアンカラ（ｓＭＶＡ）ベースのコロナウイルスワクチン |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230323389A1 (https=) |
| EP (1) | EP4153228A4 (https=) |
| JP (2) | JP7788403B2 (https=) |
| KR (1) | KR20230012583A (https=) |
| CN (1) | CN116348132A (https=) |
| AU (1) | AU2021276265A1 (https=) |
| BR (1) | BR112022023173A2 (https=) |
| CA (1) | CA3183016A1 (https=) |
| IL (1) | IL298210A (https=) |
| MX (1) | MX2022014387A (https=) |
| WO (1) | WO2021236550A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4103231A4 (en) | 2020-02-14 | 2024-03-27 | Geovax, Inc. | VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2 |
| EP4153228A4 (en) | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| WO2023056284A1 (en) * | 2021-09-29 | 2023-04-06 | Svenska Vaccinfabriken Produktion Ab | Compositions and methods for treating and preventing coronavirus infection |
| WO2023092021A1 (en) * | 2021-11-17 | 2023-05-25 | City Of Hope | Synthetic modified vaccinia ankara (smva) based coronavirus vaccines |
| EP4558171A1 (en) * | 2022-07-22 | 2025-05-28 | City of Hope | Synthetic modified vaccinia ankara vaccines to stimulate orthopox and monkeypox virus immunity |
| EP4316514A1 (en) * | 2022-08-03 | 2024-02-07 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-based vectors and their use as vaccine against sars-cov-2 |
| TW202426045A (zh) * | 2022-10-07 | 2024-07-01 | 高端疫苗生物製劑股份有限公司 | 抗新型冠狀病毒(SARS-CoV-2) Omicron變異株之免疫組合物 |
| WO2026030724A1 (en) * | 2024-08-01 | 2026-02-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sars-cov-2 vaccine |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040014034A1 (en) | 2002-06-06 | 2004-01-22 | Evans David H | Method of producing a recombinant virus |
| EP2363493B1 (en) | 2003-02-20 | 2012-11-14 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Novel insertion sites in pox vectors |
| US20070092936A1 (en) * | 2003-05-08 | 2007-04-26 | Haynes Barton F | Severe acute respiratory syndrome |
| WO2005028634A2 (en) * | 2003-09-18 | 2005-03-31 | Emory University | Improved mva vaccines |
| WO2006071250A2 (en) * | 2004-04-05 | 2006-07-06 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Soluble fragments of the sars-cov spike glycoprotein |
| DK2062023T4 (en) | 2006-08-25 | 2017-02-20 | The Government Of The Us Secretary Dept Of Health And Human Services | INTERGENIC SITES BETWEEN CONSERVATED GENES THROUGH MODIFIED VACCINIA ANKARA (VAT) VACCINIAVIRUS |
| DK2488649T3 (da) | 2009-10-16 | 2019-06-17 | Us Health | Rekombinant modificeret vaccinia ankara (mva)-vaccinia-virus indeholdende restrukturerede insertionssteder |
| US20210260181A1 (en) * | 2014-09-16 | 2021-08-26 | Altimmune, Inc | Coronavirus immunogenic compositions and uses thereof |
| EP3045181B1 (en) * | 2015-01-19 | 2018-11-14 | Ludwig-Maximilians-Universität München | A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV) |
| WO2017209053A1 (ja) | 2016-05-30 | 2017-12-07 | アステラス製薬株式会社 | 新規な遺伝子組換えワクシニアウイルス |
| JP2019535311A (ja) | 2016-11-02 | 2019-12-12 | デイビッド エバンス， | 合成キメラポックスウイルス |
| WO2018234506A2 (en) | 2017-06-21 | 2018-12-27 | Transgene Sa | PERSONALIZED VACCINE |
| WO2019014569A1 (en) * | 2017-07-13 | 2019-01-17 | City Of Hope | EXPRESSION SYSTEM FOR EXPRESSING GLYCOPROTEIN COMPLEXES OF HERPESVIRUS |
| EP3788142A4 (en) * | 2018-05-02 | 2022-04-27 | Tonix Pharma Holdings Limited | SYNTHETIC CHIMERIC VACCINE VIRUS |
| JP2023512519A (ja) | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン |
| CA3168836A1 (en) | 2020-02-03 | 2021-08-12 | City Of Hope | Poxvirus-based vectors produced by natural or synthetic dna and uses thereof |
| KR20220144416A (ko) | 2020-02-04 | 2022-10-26 | 큐어백 아게 | 코로나바이러스 백신 |
| IL295548A (en) * | 2020-02-14 | 2022-10-01 | Altimmune Inc | Immunogenic compositions of the corona virus and their uses |
| EP4103231A4 (en) | 2020-02-14 | 2024-03-27 | Geovax, Inc. | VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2 |
| GB2594683A (en) | 2020-02-17 | 2021-11-10 | Vaxbio Ltd | Vaccine |
| KR20220165731A (ko) * | 2020-02-26 | 2022-12-15 | 토닉스 파마 리미티드 | Sars-cov-2 바이러스에 대한 재조합 폭스바이러스 기반 백신 |
| WO2021178416A1 (en) * | 2020-03-02 | 2021-09-10 | Heat Biologics, Inc. | Immune-mediated coronavirus treatments |
| US11202753B1 (en) * | 2020-03-06 | 2021-12-21 | Aquavit Pharmaceuticals, Inc. | Systems and methods for generating immune responses in subjects using microchannel delivery devices |
| JP2023517286A (ja) | 2020-03-13 | 2023-04-25 | オックスフォード ユニヴァーシティ イノヴェーション リミテッド | 免疫応答を誘導するための組成物及び方法 |
| US20210299245A1 (en) | 2020-03-31 | 2021-09-30 | Sementis Limited | Attenuated poxvirus vector based vaccine for protection against covid-19 |
| US20230143228A1 (en) | 2020-04-21 | 2023-05-11 | Emory University | Coronavirus vaccines, compositions, and methods related thereto |
| EP4153228A4 (en) | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| US20220370600A1 (en) * | 2021-05-21 | 2022-11-24 | Board Of Regents, The University Of Texas System | Multigenic mva-sars-cov-2 vaccine |
-
2021
- 2021-05-17 EP EP21809653.5A patent/EP4153228A4/en active Pending
- 2021-05-17 US US17/999,170 patent/US20230323389A1/en active Pending
- 2021-05-17 BR BR112022023173A patent/BR112022023173A2/pt unknown
- 2021-05-17 KR KR1020227044240A patent/KR20230012583A/ko active Pending
- 2021-05-17 WO PCT/US2021/032821 patent/WO2021236550A1/en not_active Ceased
- 2021-05-17 JP JP2022570108A patent/JP7788403B2/ja active Active
- 2021-05-17 MX MX2022014387A patent/MX2022014387A/es unknown
- 2021-05-17 CA CA3183016A patent/CA3183016A1/en active Pending
- 2021-05-17 AU AU2021276265A patent/AU2021276265A1/en active Pending
- 2021-05-17 IL IL298210A patent/IL298210A/en unknown
- 2021-05-17 CN CN202180059838.6A patent/CN116348132A/zh active Pending
-
2025
- 2025-04-18 US US19/183,257 patent/US12584146B2/en active Active
- 2025-12-08 JP JP2025238238A patent/JP2026041921A/ja active Pending